Prostate Cancer - Results from #100

Molecular Detection of Lymph Node Metastases with One-Step Nucleic Acid Amplification (OSNA) Pooling in Prostate Cancer: The POPCORN Study. January 9, 2025

The Effect of Resistance and/or Aerobic Training on Quality of Life, Fitness, and Body Composition in Prostate Cancer Patients-A Systematic Review and Meta-Analysis. January 9, 2025

Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. January 9, 2025

Enhancing Data Completeness in Early Detection Pathway of Prostate Cancer: Integration of a Dashboard-Driven Feedback Tool to Improve Quality of Care. January 9, 2025

Prostate Cancer Risk Prediction Model Using Clinical and Magnetic Resonance Imaging-Related Findings: Impact of Combining Lesions' Locations and Apparent Diffusion Coefficient Values. January 8, 2025

Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis. January 8, 2025

Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. January 8, 2025

Clinical Feasibility of 3-D Acoustic Radiation Force Impulse (ARFI) Imaging for Targeted Prostate Biopsy Guidance. January 8, 2025

Prostate MRI and clinicopathologic risk calculator to predict laterality of extraprostatic extension at radical prostatectomy. January 8, 2025

Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. January 7, 2025

Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing. January 7, 2025

Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis. January 7, 2025

Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium. January 7, 2025

PIRADS 3 MRI lesions: are biopsies still necessary? January 7, 2025

Selective treatment de-escalation in advanced prostate cancer: have we come full circle? January 6, 2025

Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, Germany. January 6, 2025

Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes. January 6, 2025

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer. January 6, 2025

Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer. January 6, 2025

MRI-based Radiomics for Predicting Prostate Cancer Grade Groups: A Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies. January 3, 2025

Page 6 of 1455